Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 166

1.

Temporal and molecular dynamics of human metastatic breast carcinoma cell adhesive interactions with human bone marrow endothelium analyzed by single-cell force spectroscopy.

Xie L, Sun Z, Hong Z, Brown NJ, Glinskii OV, Rittenhouse-Olson K, Meininger GA, Glinsky VV.

PLoS One. 2018 Sep 20;13(9):e0204418. doi: 10.1371/journal.pone.0204418. eCollection 2018.

2.
3.

Do MCF7 cells cope with metformin treatment under energetic stress in low glucose conditions?

Dogan Turacli I, Umudum H, Pampal A, Candar T, Kavasoglu L, Sari Y.

Mol Biol Rep. 2018 Jun;45(3):195-201. doi: 10.1007/s11033-018-4152-5. Epub 2018 Feb 3.

PMID:
29397517
4.

Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.

Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Ricci A.

Int J Mol Sci. 2018 Jan 26;19(2). pii: E379. doi: 10.3390/ijms19020379. Review.

5.

Differential expression of PIWIL2 in papillary thyroid cancers.

Erdogdu IH, Yumrutas O, Ozgur Cevik M, Bozgeyik I, Erdogdu M, Inan HM, Bagis H.

Gene. 2018 Apr 5;649:8-13. doi: 10.1016/j.gene.2018.01.066. Epub 2018 Jan 31.

PMID:
29369786
6.

Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.

Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S.

Gastroenterology. 2018 Apr;154(5):1524-1537.e6. doi: 10.1053/j.gastro.2017.12.014. Epub 2017 Dec 21.

PMID:
29274868
7.

Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.

Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T.

J Am Heart Assoc. 2017 Nov 8;6(11). pii: e006513. doi: 10.1161/JAHA.117.006513.

8.

Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.

Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P.

Nat Commun. 2017 Oct 6;8(1):793. doi: 10.1038/s41467-017-00925-6.

9.

Functional impact of Galectin-3 and TRAIL expression in breast cancer cells.

Liu XH, Deng CX, Hu PC, Wang Y, Dong YH.

Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3626-3633.

10.

Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.

Piyush T, Chacko AR, Sindrewicz P, Hilkens J, Rhodes JM, Yu LG.

Cell Death Differ. 2017 Nov;24(11):1937-1947. doi: 10.1038/cdd.2017.119. Epub 2017 Jul 21.

11.

Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology.

Sciacchitano S, Lavra L, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Trovato M, Drago C, Bartolazzi A.

Oncotarget. 2017 Jul 25;8(30):49421-49442. doi: 10.18632/oncotarget.17220. Review.

12.

Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer.

De Iuliis F, Salerno G, Taglieri L, Lanza R, Cardelli P, Scarpa S.

Int J Biol Markers. 2017 Jul 24;32(3):e333-e336. doi: 10.5301/ijbm.5000262.

PMID:
28430337
13.

Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules.

Sciacchitano S, Lavra L, Ulivieri A, Magi F, Porcelli T, Amendola S, De Francesco GP, Bellotti C, Trovato MC, Salehi LB, Bartolazzi A.

Endocrine. 2016 Oct;54(1):139-147. Epub 2015 Oct 16.

PMID:
26475496
14.

Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.

Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC, Woodward WA, Buchholz TA, Acklin K, Ramirez K, Hafley M, Alt E, Vykoukal J, Bresalier RS.

Breast Cancer Res. 2016 Sep 29;18(1):97. doi: 10.1186/s13058-016-0757-6.

15.

Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.

Hilakivi-Clarke L, Wärri A, Bouker KB, Zhang X, Cook KL, Jin L, Zwart A, Nguyen N, Hu R, Cruz MI, de Assis S, Wang X, Xuan J, Wang Y, Wehrenberg B, Clarke R.

J Natl Cancer Inst. 2016 Sep 8;109(1). pii: djw188. doi: 10.1093/jnci/djw188. Print 2017 Jan.

PMID:
27609189
16.

Biomarkers of cardiac injury in patients undergoing thoracic radiation therapy.

Serrano NA, Mikkelsen R, Canada J, Mezzaroma E, Weiss E, Abbate A.

Int J Cardiol. 2016 Nov 15;223:507-509. doi: 10.1016/j.ijcard.2016.08.263. Epub 2016 Aug 15. No abstract available.

17.

The deficiency of galectin-3 in stromal cells leads to enhanced tumor growth and bone marrow metastasis.

Pereira JX, Azeredo MC, Martins FS, Chammas R, Oliveira FL, Santos SN, Bernardes ES, El-Cheikh MC.

BMC Cancer. 2016 Aug 15;16:636. doi: 10.1186/s12885-016-2679-1.

18.

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.

Iwai T, Sugimoto M, Harada S, Yorozu K, Kurasawa M, Yamamoto K.

Oncol Rep. 2016 Aug;36(2):626-32. doi: 10.3892/or.2016.4902. Epub 2016 Jun 22.

19.

Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.

Grosset AA, Labrie M, Vladoiu MC, Yousef EM, Gaboury L, St-Pierre Y.

Oncotarget. 2016 Apr 5;7(14):18183-203. doi: 10.18632/oncotarget.7784.

20.

Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.

Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R, Raz A.

Cancer Res. 2016 Mar 15;76(6):1391-402. doi: 10.1158/0008-5472.CAN-15-1793. Epub 2016 Feb 2.

Supplemental Content

Loading ...
Support Center